|
|
|
|
By: Oliverson, et al. (Senate Sponsor - Hughes) |
H.B. No. 1283 |
|
(In the Senate - Received from the House May 4, 2023; |
|
May 5, 2023, read first time and referred to Committee on Health & |
|
Human Services; May 18, 2023, reported favorably by the following |
|
vote: Yeas 8, Nays 0; May 18, 2023, sent to printer.) |
Click here to see the committee vote |
|
|
|
|
|
COMMITTEE VOTE |
|
|
|
|
YeaNayAbsentPNV |
|
KolkhorstX |
|
PerryX |
|
BlancoX |
|
HallX |
|
HancockX |
|
HughesX |
|
LaMantiaX |
|
MilesX |
|
SparksX |
|
|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
|
relating to prescription drug formularies applicable to the |
|
Medicaid managed care program. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. Section 533.005(a-1), Government Code, is |
|
amended to read as follows: |
|
(a-1) The requirements imposed by Subsections (a)(23)(A), |
|
(B), and (C) do not apply, and may not be enforced, on and after |
|
August 31, 2033 [2023]. |
|
SECTION 2. If before implementing any provision of this Act |
|
a state agency determines that a waiver or authorization from a |
|
federal agency is necessary for implementation of that provision, |
|
the agency affected by the provision shall request the waiver or |
|
authorization and may delay implementing that provision until the |
|
waiver or authorization is granted. |
|
SECTION 3. This Act takes effect September 1, 2023. |
|
|
|
* * * * * |